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Individuals who control HIV infection despite not being treated with antiretroviral 
therapeutics, deemed Elite Controllers or Suppressors (ES), represent a model for a 
functional cure. MHC class I alleles HLA-B*57 and HLA-B*27 have been associated with 
the ES phenotype, suggesting a genetic component. Accordingly, the role of CD8+ T 
cells in the ability to control infection is an ongoing field of investigation. ES have 
qualitatively greater CTL responses to HIV infection in in vitro and ex vivo assays. HIV 
often escapes from CTL pressure by mutating epitopes that are presented by MHC 
molecules. These CTL escape mutations can prevent CD8-mediated killing if the 
infected host cannot recognize these modified viral epitopes. Interestingly, escape 
variants are often found in the plasma of ES but not in integrated HIV-proviral genomes. 
In this thesis, I will present evidence that ES can suppress viral replication in CD4+ T 
cells that are infected with HIV variants harboring CTL escape mutations. 
While ES have qualitatively more effective CD8+ T cells ex vivo, this does not 
preclude other possible factors from being critical to the phenotype. The frequency of 
latently infected CD4+ T cells in the periphery of ESs is significantly lower than in 
chronically infected individuals; this phenotype is not due to an inability for the CD4+ T 
cells to be infected. The amount of intracellular RNA in infected cell types has not been 
well characterized. We hypothesized that ongoing viral replication due to a lack of 
antiretroviral therapy may lead to increased baseline cell associated HIV-1 mRNA levels, 
which may allow for greater CTL-mediated clearance of HIV, in turn keeping the size of 
the HIV-infected CD4 population low. Here we characterize baseline and induced 
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ES are HIV-infected individuals who control viremia without antiretroviral 
therapy1,2,3,4. Due to the very low level of viremia, these individuals almost never, if ever, 
transmit virus to a new host. Additionally, ES rarely lose control and progress to AIDS. 
Understanding the mechanism by which these individuals are able to control HIV 
infection could lead to the discovery of a functional cure for HIV. Early studies suggested 
that these individuals were merely infected with a defective HIV variant5,6. While infection 
with replication deficient viral strains may lower the burden to control HIV infection, many 
ES are infected with fully replication competent strains7,8,9,10. 
Nevertheless, it is entirely possible that control is merely happenstance. ES may 
be the individuals who reside in one tail of a normal distribution centered around some 
median viral load11. While this idea is difficult to disprove, there does exist, to some 
degree, a hierarchy of HLA alleles with respect to the ability to control viremia12,13; this 
suggests that immune pressure is involved in control of viremia. Also, ES 
disproportionately possess HLA-B*57 and HLA-B*27 alleles compared to the general 
population, both seronegative and seropositive14,15,16,17,18,19,20. This association of HLA 
molecules with control of viremia strongly suggests a genetic component to the ES 
phenotype, specifically a CD8-mediated mechanism of control. 
Possessing protective HLA alleles is not sufficient for immune-mediated HIV 
control. Upon stimulation with HIV peptides, HIV-specific CD8+ T cells isolated from the 
periphery proliferate and generate cytokines; peptide stimulation of CD8+ T cells incurs 
a more robust phenotype in ESs than MHC-matched individuals who do not control18,21 
(Chronic Progressors, or CPs). Additionally, coculturing CD8+ T cells isolated from the 
blood of ES with HIV-infected autologous CD4+ T cells results in greater inhibition of 
viral production than observed in CP counterparts22.  
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HIV evades this CTL pressure in vivo by generating mutations in MHC-restricted 
epitopes. These CTL escape mutations are either not processed, loaded, or recognized 
properly, and the ternary complex cannot form. CD4+ T cells from ES generally harbor 
few CTL escape mutations, whereas CPs often harbor several23. Interestingly, escape 
variants can be found in the plasma of ES, and this does not necessarily lead to loss of 
control24. In chapter 1, we will characterize the ability for CD8+ T cells to respond to 
stimulation with either wild type or escape variant HIV Gag peptides and suppress viral 
infection in CD4+ T cells infected with HIV variants that either do or do not contain CTL 
escape mutations. 
Without antiretroviral therapy, the low level of plasma viremia observed in ES 
may be a result of ongoing replication. Antiretroviral therapy is believed to halt viral 
replication25,26. Without ongoing replication, antigen cannot be presented to CD8+ T 
cells, and CTL responses will dissipate27,28. If ES experience ongoing replication, CD8+ 
T cells will be continually primed for infection, improving the cytotoxic capacity of CD8+ T 
cells in a way that may not be translatable to CPs. It is poorly understood what the 
baseline levels of cell-associated HIV mRNA are and if these levels are due to ongoing 





CHAPTER 1: CD8+ T CELLS FROM HLA-B*57 ELITE SUPPRESSORS 
EFFECTIVELY SUPPRESS REPLICATION OF HIV-1 ESCAPE MUTANTS. 




Elite Controllers or Suppressors (ES) are HIV-1 positive individuals who maintain plasma 
viral loads below the limit of detection of standard clinical assays without antiretroviral 
therapy. Multiple lines of evidence suggest that the control of viral replication in these 
patients is due to a strong and specific cytotoxic T lymphocyte (CTL) response. The 
ability of CD8+ T cells to control HIV-1 replication is believed to be impaired by the 
development of escape mutations. Surprisingly, viruses amplified from the plasma of ES 
have been shown to contain multiple escape mutations, and it is not clear how 
immunologic control is maintained in the face of virologic escape. 
Results 
We investigated the effect of escape mutations within HLA*B-57-restricted Gag epitopes 
on the CD8+ T cell mediated suppression of HIV-1 replication. Using site directed 
mutagenesis, we constructed six NL4-3 based viruses with canonical escape mutations 
in one to three HLA*B-57-restricted Gag epitopes. Interestingly, similar levels of CTL-
mediated suppression of replication in autologous primary CD4+ T cells were observed 
for all of the escape mutants. Intracellular cytokine staining was performed in order to 
determine the mechanisms involved in the suppression of the escape variants. While low 
baseline CD8+ T cells responses to wild type and escape variant peptides were seen, 
stimulation of PBMC with either wild type or escape variant peptides resulted in 




These data presented demonstrate that CD8+ T cells from ES are capable of 
suppressing replication of virus harboring escape mutations in HLA-B*57-restricted Gag 
epitopes. Additionally, our data suggest that ES CD8+ T cells are capable of generating 
effective de novo responses to escape mutants. 
BACKGROUND 
In primary HIV-1 infection, vigorous viral replication results in plasma virus levels as high 
as one million copies/mL of HIV-1 RNA. As cellular immune responses develop, plasma 
virus levels decrease, and a viral set point is established. A subset of HIV-1-infected 
individuals known as Elite Controllers or Suppressors (ES), maintain a viral set point 
below the limit of detection of standard clinical assays (<50 copies of HIV-1 RNA/mL of 
blood1,2,3,4). Early studies suggested that some long-term non-progressors (LTNPs) and 
ES are infected with defective viruses5,6. In contrast, more recent studies have 
determined that many ES are infected with viruses that are fully replication competent, 
suggesting that host factors rather than infection by defective virus are responsible for 
ES status7,8,9,10,29. 
Some HLA alleles affect disease progression, including HLA-B*27, HLA-B*51, HLA-
B*57/58, and HLA-B*3512,30. Multiple cohort studies have demonstrated that the HLA-
B*57 allele is overrepresented in ES14,15,16,17,18,19,20. This finding has been confirmed by 
multiple GWAS studies31,32,33,34,35,36. However, the majority of HIV-1-infected HLA-
B*57+ patients develop progressive disease, and are thus termed chronic progressors 
(CPs)14. The protection conferred by HLA-B*57 and HLA-B*27 is thought to be mediated 
by effective CD8+ T cell responses against conserved immunodomniant epitopes that 
are presented by MHC class I proteins18,21,22,37,38,39,40. Comparison studies of HLA-
B*57+ ES and CPs have provided some details about the elite suppressor phenotype. 
Stimulation of bulk peripheral blood mononuclear cells (PBMCs) with Gag peptides 
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induces greater proliferation as well as more robust granzymes A/B and perforin 
expression in CD8+ T cells from HLA-B*57+ ES compared to HLA-B*57+ CPs18. 
Some nonsynonymous mutations in epitopes enable the virus to escape from the 
cytotoxic T lymphocyte (CTL) responses. The role these escape mutations play in 
determining protection versus progression in HLA-B*57 positive patients is controversial. 
A correlation between the number of HLA-B*57 Gag epitopes and the level of viremia 
was observed in a cohort of HLA-B*5703 positive patients with Clade C HIV-1 
infection41. In another study, the development of escape mutations was temporally 
associated with virologic breakthrough in a patient who had maintained undetectable 
viral loads for a year after infection34. In contrast, studies of early infection in other HLA-
B*57/5801 positive patients have not found a correlation between the accumulation of 
escape mutations and virologic breakthrough43,44. Furthermore, one study found no 
difference in the frequency of escape mutations in HLA-B*57-restricted epitopes in 
proviral clones amplified from ES when compared to CPs45; other studies found that 
while escape mutations were largely absent from provirus amplified from CD4+ T cells of 
ES, virus amplified from the plasma of the same subjects contained a high frequency of 
escape mutations24,46. In this study, we sought to explain how ES maintain undetectable 
levels of plasma virus despite the presence of circulating HIV-1 isolates that contain 
numerous escape mutations. Specifically, we asked whether CD8+ T cells from these 
patients were capable of inhibiting the viral replication of engineered escape mutants. 
We demonstrate that ES can inhibit the replication of escape variant HIV-1 and suggest 
that these patients are capable of generating protective de novo responses against the 
escape mutant variants. This work has implications for the design of therapeutic T cell 




Effect of escape mutations in HLA-B*57-restricted Gag epitopes on viral fitness 
The effect of several escape mutations on viral fitness has been explored in vivo and in 
vitro47,48,49,50,51,52. We focused on escape mutations in the three HLA-B*5703 restricted 
Gag epitopes: IW9 (Gag 147–155), KF11 (Gag 162–172), and TW10 (Gag 240–249). 
We have previously demonstrated that HLA-B*5703 positive ES in our cohort do not 
target the fourth HLA-B*57-restricted Gag epitope QW9 (Gag 308–316)24 and therefore 
we did not include this epitope in our analysis. To address the fitness cost of these 
escape mutations, we introduced a series of mutations into the reference isolate NL4-3 
and generated GFP-expressing HIV-1 pseudoviruses carrying these mutations. Virus 
concentrations were measured in triplicates by RT-PCR. We then infected PHA-
activated CD4+ T cells from four seronegative healthy donors using a 2 log range of virus 
inoculums. Infection curves for the seven viruses are shown in Figure 1A. 
Infectivity relative to the reference clone NL4-3 was taken as a measure of fitness. 
Infectivity curves plateaued at different points for different mutants. A best fitting curve 
was generated with GraphPad to calculate a nonlinear least squares regression model 
and was used to determine the theoretical maximal infection. Figure S1 shows the best 
fit curve for each of the assayed viruses. This theoretical maximal infection was used to 
determine the relative percentage of maximal infection relative to the reference clone 
NL4-3 (Figure 1B). The I147L and A146P mutations, which are found in the IW9 epitope 
of p24, each had a minimal effect on viral fitness with calculated fitness levels of 88 
percent and 90 percent respectively compared to unmutated NL4-3. The A163S 
mutation (72 percent relative fitness) had a larger effect on fitness consistent with a prior 
study that showed that mutations in this epitope in Clade C virus had a major impact on 
replication capacity41. When the A163S mutation was combined with the A146P 
mutation, a further decrease in fitness was observed (50 percent relative fitness). The 
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T242N/G248A variant had an intermediate level of fitness (67 percent relative fitness). 
Interestingly, the A146P/A163S/T242N/G248A variant (49 percent relative fitness) 
showed no additional loss of fitness than what was observed with the A146P/A163S 
variant. 
ES CD8+T cells suppress replication of viruses containing CTL escape mutations 
We next determined whether CD8+ T cells from ES could inhibit the infection of viruses 
harboring escape mutations. We isolated CD4+ and CD8+ T cells from seven HLA-
B*5703+ ES and five healthy seronegative donors. The ES did not have any other 
protective alleles. Unstimulated CD4+ T cells were infected with each variant individually 
and were co-cultured with unstimulated CD8+ T cells at various effector to target ratios 
for three or five days. Interestingly, unstimulated CD8+ T cells from ES were capable of 
suppressing each variant (Figure 2A), whereas healthy donors had no suppressive 
capabilities (Figure 2D). The percentage of suppression decreased at lower effector to 
target ratios. Compared to day three, day five showed increased levels of suppression at 
all effector to target ratios (Figure 2A). 
A prior study demonstrated that CD8+ T cells that were stimulated with peptides were 
more effective at eliminating HIV-1 infected target cells18. We therefore stimulated 
PBMCs from the same group of ES and healthy donors with a combination of three wild 
type peptides (wild type IW9, wild type KF11, and wild type TW10) or a combination of 
three escape variant peptides (mutant IW9 (I147L), mutant KF11 (A163S), or mutant 
TW10 (T242N/G248A)) in the presence of 10 units/mL IL-2. After seven days of 
stimulation, CD8+ T cells from both stimulation groups were individually isolated and 
cultured with unstimulated CD4+ T cells that were infected with either wild type virus or 
one of the 6 escape mutants. Interestingly, there was no statistical difference in the 
suppressive capacity of CD8+ T cells that were stimulated with either wild type or escape 
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variant peptides (Figure 2B, C and Figure S2). Figure 3 shows the suppressive ability of 
unstimulated CD8+ T cells from each patient at day three and day five. Statistically 
significant differences in levels of suppression between wild type and escape variants 
were seen only for A163P at a one to two effector to target ratio (Figure 3A); this 
difference was not seen at any other effector to target ratios. Taken together, these 
results demonstrate that ES are capable of recognizing escape variant epitopes as 
effectively as their non-mutated counterparts.   
Stimulation of CD8+T cells with wild type or escape variant peptides increases 
expression of interferon γ and perforin 
To determine the mechanism of CTL suppression of escape mutants, we analyzed the 
expression of IFN-γ and perforin in freshly isolated CD8+ T cells and CD8+ T cells that 
were primed with either wild type or escape variant peptides. Freshly isolated PBMCs 
and PBMCs from each stimulation group were stimulated overnight with individual wild 
type or escape variant peptides. Freshly isolated CD8+ T cells were observed to have 
very low levels of IFN-γ expression in response to each peptide (Figure 4A, B, C left 
panel). In contrast, culture of PBMCs with wild type peptides over a 7 day period prior to 
overnight stimulation with wild type peptides resulted in a statistically significant increase 
(P < 0.05) in IFN-γ expression (Figure 4A, B, C center panel). A similar response was 
seen when the CD8+ T cells were stimulated with the analogous escape variant peptide. 
Interestingly, IFN-γ expression in response to restimulation with wild type or escape 
variant peptides individually were similar in CD8+ T cells that were cultured for 7 days in 
the presence of either wild type or escape variant peptides (Figure 4A, B, C right panel). 
Because perforin expression is associated with CTL-mediated killing18,39,53, we also 
examined perforin expression by stimulated CD8+ T cells. Low levels of perforin and 
IFN-γ double positive cells were observed when freshly isolated CD8+ T cells were 
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stimulated with wild type or escape variant peptides (Figure 4D, E, F left panel). In 
contrast, CD8+ T cells that had been cultured for 7 days in the presence of wild type or 
escape variant peptide cocktails were observed to have an increase in the percentage of 
IFN-γ and perforin double positive CD8+ T cells when stimulated overnight with either 
wild type or escape variant peptides. Interestingly, culturing PBMCs in the presence of 
wild type peptides or escape variant peptide cocktails resulted in similar levels of CD8+ T 
cells that co-expressed IFN-γ and perforin in response to overnight peptide stimulation. 
Additionally, overnight stimulation with KK10 (Gag 263–272), an immunodominant HLA-
B*27 specific peptide, resulted in no increase in IFN-γ or perforin expression, confirming 
the specificity of the enhanced CD8+ T cell responses to the HLA-B*57-restricted 
peptides. 
To determine whether similar responses were present in HLA-B*57 positive CPs, we 
also analyzed CD8+ T cells from five CPs on suppressive HAART regimens, two CPs 
who recently had detectable viremia, and one CP with high levels of viremia who was 
not on HAART. With freshly isolated PBMCs, there was very low IFN-γ expression on 
CD8+ T cells in response to overnight stimulation with peptides (Figure 5A, B, C left 
panel). Stimulation of cells with wild type peptides or escape variant peptides induced an 
increase in IFN-γ expression by CD8+ T cells in some patients after overnight stimulation 
with TW10 or KF11 (Figure 5A, B, C center and right panels). The percentage of CD8+ T 
cells that co-expressed IFN-γ and perforin increased from the unprimed baseline 
(Figure 5E, F, G), though generally not as dramatically as the increase seen in ES. This 
is consistent with the enhanced proliferative capacity of ES HIV-specific CD8+ T 
cells18,21. Interestingly, the patients on HAART who recently had detectable levels of 
viremia had higher responses than the patients on suppressive HART regimens who 




CTL responses against Gag epitopes have been associated with virologic control54,55,56 
and Gag-specific CD8+ T cells can target incoming virions and therefore have the 
potential to kill cells prior to productive infection57,58,59,60,61. The CTL response has been 
associated with the appearance of escape mutations in HIV and SIV infection. The 
mechanism of escape observed for individual mutations can vary. Mutations can affect 
epitope processing, stability of peptides, MHC:peptide complex stability, or TCR 
recognition of the MHC:peptide complex. Mudd et al. observed that Mamu-B*00801 
macaques that controlled viral infection acquired few, if any, escape mutations in Vif and 
Nef epitopes, whereas macaques that progressed acquired several during the acute 
phase, suggesting that control may result from a immunologic pressure that prevents the 
appearance of escape mutations62. In contrast, Migueles et al. found that there was no 
difference between HLA-B*57+CPs and HLA-B*57+ ES in the frequency of escape 
mutations in Gag45, and Bailey et al. found a high frequency of escape mutations in HLA-
B*57-restricted epitopes present in virus amplified from ES plasma24,46. 
In this study, we sought to determine how ES maintain control of viral replication despite 
circulating escape mutant viruses in the plasma. We constructed a series of mutants that 
contained commonly observed HLA-B*57 restricted Gag escape mutations. While our 
study is limited by the fact that we did not study viral inhibition of autologous escape 
mutants isolated from each ES, the A146P and T242N/G248A mutations in the IW9 and 
TW10 epitopes are commonly seen in our cohort24. Mutations in KF11 are rare in Clade 
B HIV-1 isolates, but one patient was found to have the A163S mutation and we 
demonstrated that this was in fact an escape mutation in a prior study24. In agreement 
with other studies47,48,49,50,51, we found that some of the escape mutants we generated 
were detrimental to viral fitness. While attenuating escape mutations may contribute to 
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elite control63, viruses from CPs have been observed to have similar escape mutations, 
although compensatory mutations may partially restore viral fitness64,65. 
Klenerman and Zinkernagel demonstrated a limitation to the adaptive immune response: 
original antigenic sin66. In brief, when CTLs respond to an intracellular pathogen, any 
variant of the original pathogen elicits the activation of the original memory response, 
which is potentially less effective in the face of the new variant of the pathogen67. 
Allen et al.demonstrated in a cohort of HLA-A*11+ individuals that the CTL response that 
recognizes escape variants was incapable of recognizing the original, un-mutated 
variants, as these CD8+ T cells express unique Vβ segments68. New CTL responses 
have been shown to arise not only during the acute phase, but during chronic infection in 
HLA-A*02+ patients69. Lichterfeld et al. have shown that HLA-B*27+ individuals can 
develop a de novo response to the immunodominant KK10 L268M escape mutation 
during chronic infection70. In a previous study, HLA-B*57/58+ children infected perinatally 
showed a remarkable ability to generate de novo CD8+ T cell responses to escape 
mutations in the TW10 Gag epitope. Interestingly, there was little recognition of the wild 
type TW10 epitope in these children71. Another study found that CD8+ T cells from both 
HLA-B*57+ ES and HLA-B*57+ viremic patients made responses to autologous TW10 
escape variant peptides72. Furthermore, we previously have described CD8+ T cell de 
novo responses to escape mutants in HLA-B*57+ES24,73. 
While of all these studies examined IFN-γ responses, secretion of this cytokine is not a 
correlate of immunity in HIV infection74,75. Furthermore, discrepancies between IFN-γ 
ELISPOT assays and CD8+ T cell-mediated killing of both SIV and HIV escape variants 
have been reported76,77. Therefore in order to determine whether protective de novo 
responses were present in ES, we looked at the ability of CD8+ T cells to suppress 
replication of escape mutants. We used the suppression assay because Saez-Cirion and 
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colleagues have demonstrated that the ability of unstimulated primary CD8+ T cells to 
inhibit viral replication correlates with elite control of HIV-1 infection78,80, and we have 
recently confirmed this finding79. In a prior study, we demonstrated that CD8+ T cells 
from an HLA-B*57 ES suppressed multiple rare autologous TW10 escape variants by a 
non-cross reactive de novo response81. In the current study, we demonstrated that this 
phenomenon is not limited to that one ES or to rare TW10 epitopes. CD8+ T cells from 
multiple HLA-B*5703+ ES were able to suppress the replication of virus containing 
common escape mutations in all three HLA-B*5703-restricted Gag epitopes. This is 
probably due to the development of CD8+ T cells that produce perforin in response to 
wild type and escape variant peptides. 
Interestingly, while the presence of residual intracellular concentrations of antiretroviral 
drugs prevented us from infecting CD4+ T cells and performing the suppression assay 
with cells from HLA-B*57+ CPs, we demonstrated de novo IFN-γ production when 
CD8+ T cells of some CPs were stimulated with variant peptides. This is consistent with 
an earlier study which showed that HLA-B*57+ CPs made IFN-γ responses to 
autologous TW10 variants that were as strong, if not stronger, than the responses made 
by HLA-B*57+ ES72. Thus the elite control of viral replication is not solely due to the 
ability to recognize escape mutants. Rather, our work suggests that ES maintain control 
of viremia in spite of virologic escape in immunodominant epitopes because they 
develop protective CD8+ T cell responses to the escape variants. In contrast, CPs 
generally do not develop protective CTL responses18,21,39,53,78,79,80, and a study that 
compared HLA-B*57+ ES to HLA-B*57+ CPs found that proliferative CTL responses as 
well as perforin secretion in response to HIV antigens correlated strongly with elite 
suppression21. Interestingly, we show here that stimulation with wild type and escape 
variant peptides can induce perforin responses to both peptides in some CPs. Thus, it 
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may be possible to immunize subjects with both wild type and escape variant peptides in 
order to induce protective CD8+ T cell responses that will prevent the emergence of 
common escape mutations. Taken together, it appears that ES CD8+ T cells may 
develop effective CTL suppressive responses to escape variants; these responses in 
addition to the reduced fitness of the escape variants, may explain how ES maintain 
levels of viremia in the face of virologic escape. 
CONCLUSION 
In this study, we demonstrate the ability of CD8+ T cells from ES to suppress replication 
of viruses harboring escape mutations in HLA-B*57-restricted Gag epitopes. The 
reduced fitness of these escape mutants may also contribute to elite control. 
Additionally, protective de novo CD8+ T cell responses to both wild type and escape 
variant peptides could be generated in ES and some CPs by priming PBMCs with either 
peptide. Induction of CD8+ T cells that could respond to wild type virus as well as 
common escape mutants would be advantageous for a CTL-based vaccine. 
MATERIALS AND METHODS 
Consent 
All studies were approved by the Johns Hopkins Institutional Review Board. All patients 
and HIV negative donors provided written informed consent before participation in this 
study. 
Construction of escape mutant viruses 
Single-round infection by pseudotyped NL4-3 virus has been previously described82. In 
brief, eGFP was introduced in theenv reading frame of pNL4-3, thus creating 
an env deficient pNL4-3 that allows for analysis of infected cells by flow cytometry. 
Individual point mutations were introduced by site directed mutagenesis (Agilent 
Technologies QuikChange II kit) and primers: A146P 5′ 
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ggcaaatggtacatcagcccatatcacctagaactttaaatgc, I147L 5′ 
ggtacatcaggccctatcacctagaactttaaatgcatgg, A164S 5′ 
ggtaaaagtagtagaagagaagtctttcagcccagaagtaatacc, and T242N/G248 5′ 
cccttcaggaacaaatagcgtggatgacacataatccacc followed by 5′ 
ggaactactagtaaccttcaggaacaaatagcgtgg. A146P/A163S was made by sequential 
mutagenesis. A146P/A163S/T242N/G248A was made by insertion of the digestion 
product of T242N/G248A with SpeI and SbfI into the A146P/A163S plasmid. These 
plasmids were sequence confirmed and individually cotransfected with pCI containing 
the III-B env reading frame into HEK293T cells using Lipofectamine 2000. 48 hours after 
transfection, supernatant was collected and virus was isolated by ultracentrifugation at 
50,000 × g through a 20% sucrose cushion for 2 h. 
PBMC peptide stimulation 
PBMCs were isolated from blood of ES, CP, and healthy donors by Ficoll gradient 
centrifugation. PBMCs were then cultured in RPMI 1640 supplemented with 10% FBS 
and 10 units/mL IL-2 in the presence of either 10 ug/mL total of TW10, KF11, and IW9 
peptide (3 ug/mL each), or corresponding peptides containing escape mutations, for 
7 days, with IL-2 supplemented every 48 h. 
CD8+ And CD4+T cell isolation 
PBMCs were isolated by Ficoll gradient centrifugation. CD8+ T cells were isolated from 
PBMC using the Miltenyi Human CD8 Microbeads according to the manufacturer’s 
instructions. CD4+ T cells were isolated from either bulk PBMCs or CD8-depleted 
PBMCs using the Miltenyi Human CD4+ T Cell Isolation Kit II according to the 
manufacturer’s instructions. Purity of both cell types was routinely greater than 95% as 




Freshly isolated CD4+ T cells were spinoculated as described83 at 1,200 × g for 2 h with 
one of seven NL4-3 pseudotyped viruses in 2.9 × 106 cells/tube. We typically used 50 to 
100 ng p24 virus for 100,000 CD4+ T cells which typically resulted in 2 to 10% GFP 
positive cells. Cells without virus were spinoculated as a negative control. After 
spinoclulation, CD4+ T cells were washed and plated in a 96 well plate at 0.1 × 105 cells / 
well in RPMI 1640 supplemented with 10% FBS. Unstimulated, wild type stimulated, or 
Mutant stimulated CD8+ T cells were immediately added to the spinoculated CD4+ T 
cells, at specified ratios. Cells were cultured for 3 or 5 days before fixation and staining 
(CD3 Pacific Blue, CD8 APC, BD) and analysis by flow cytometry on a FACSCanto II 
(BD). 
Intracellular cytokine analysis 
0.5 × 106 unstimulated or stimulated PBMCs (from above) were restimulated with 
peptide (2 ug/mL), anti-CD28, and anti-CD49d in the presence of GolgiStop and 
GolgiPlug (BD) for 12 h. After staining with CD3 PE and CD8 APC-H7 (BD), cells were 
fixed and permeablized with Cytoperm/Cytofix Kit (BD). Cytokines were stained using 
IFN-γ PerCP-Cy5.5 (BD) and Perforin FITC (Cell Sciences). Stained cells were analyzed 
by flow cytometry on a FACSCanto II (BD). 
Viral quantification 
Concentrated virus was quantified by q-RTPCR. Viral RNA was isolated in triplicate with 
ZR Viral RNA Kit (Zymogen), and RT was performed using Superscript III First-Strand 
Synthesis Kit (Invitrogen) using poly(dT)20 primers. VQA qPCR was performed as 
described84. In brief, Taqman Fast Advanced Master Mix (Invitrogen) was used with 





PBMCs were isolated from healthy donors by Ficoll gradient centrifugation and activated 
in RPMI 1640 supplemented with IL-2 (100 units/mL) and PHA (1 ug/mL) for 3 days. 
CD4+ T cells were isolated (as above) and spinoculated (1,200 × g, 2 h) in a 96-well 
plate with 0.1 × 106 cells / well, with different concentrations of each virus as shown in 
Figure 1. 72 h after spinoculation, cells were fixed (3.3% formaldehyde) and the level of 
infection for each concentration of virus was analyzed by flow cytometry on a 
FACSCanto II (BD). GraphPad Prism was used to generate model curves. Relative 
fitness was determined as a percentage of the maximal infection of an individual virus 







Fitness cost of canonical HLA-B*57 escape mutations. A. Average infection by 
seven NL4-3 escape variants in uninfected individuals. Viral inoculum was quantified by 
relative qPCR. 105 CD4+ T cells were infected in a 96-well plate in triplicate. Infection 
was determined by GFP expression by flow cytometry. Wild type NL4-3 (black) showed 
the highest level of infection, while NL4-3 escape mutant variants showed reduced 
maximal infection (I147L, orange; A146P, navy; A163S, red; A146P/A163S, purple; 
T242N/G248A, brown; A146P/A163S/T242N/G248A, teal). Error bars represent SEM. 








Suppression of replication of NL4-3 escape variant viruses. A-C: Unstimulated 
CD4+ T cells from HLA-B*5703 positive ES were infected with one of seven NL4-3 
variants (wild type, black; I147L, orange; A146P, navy; A163S, red; A146P/A163S, 
purple; T242N/G248A, brown; A146P/A163S/T242N/G248A, teal) and cultured with 
autologous CD8+ T cells isolated from fresh PBMCs (A)or PBMCs stimulated with either 
wild type (B) or escape variant (C) HLA-B*57- Gag restricted Gag peptides for 7 days 
before isolation. CD8+ T cells were co-cultured with infected CD4+ T cells at three 
effector to target ratios. D-F: Unstimulated CD4+ T cells from healthy donors were 
infected with one of the seven NL4-3 variants used above and co-cultured with CD8+ T 
cells as was done with ES (D, unstimulated; E, wild type peptide stimulated; F, escape 
variant stimulated). Infection of CD4+ T cells was quantified by flow cytometry on days 3 
(left) and 5 (right) after infection by GFP expression. Median values are plotted. For ES, 







Individual suppression of NL4-3 escape variant viruses. Unstimulated CD4+ T cells 
from HLA-B*5703+ ES were infected with one of seven NL4-3 variants (wild type, black; 
I147L, orange; A146P, navy; A163S, red; A146P/A163S, purple; T242N/G248A, brown; 
A146P/A163S/T242N/G248A, teal) and cultured with autologous unstimulated 
CD8+ cells at three effector to target ratios. A shows maximal suppression on day 
3; B shows maximal suppression on day 5. Black horizontal bars indicate median. 






Intracellular cytokine staining of ES CD8 + T cells. A-D: CD8+ T cells of HLA-B*57 
positive ES were either freshly isolated (left) or stimulated with either wild type (center) 
or escape variant (right) HLA-B*57-restricted Gag peptides for 7 days. Cells from each 
group underwent an overnight stimulation with individual peptides. Percentage of CD8+ T 
cells expressing IFN-γ when stimulated overnight with TW10 (A), KF11 (B), and 
IW9 (C) in blue, or the escape mutant variant peptide containing T242N/G248A (A), 
A163S(B), and I147L (C) mutations in red is shown. E-H: Percentage of CD8+ T cells 
expressing both IFN-γ and perforin after restimulation with TW10 (E), KF11 (F), and 
IW9 (B) in blue, or the escape mutant variant peptide containing T242N/G248A (E), 
A163S (F), and I147L(G) in red is shown. D and H show CD8+ T cells that express IFN-γ 
or co-express IFN-γ and perforin when PBMCs were stimulated overnight with Gag 263-
272 (KK10, HLA-B*27+ peptide). Black horizontal bars indicate statistically significant 
difference (P < 0.05) between samples when stimulated overnight with the same variant 
peptide; gray horizontal bars indicate statistically significant difference (P < 0.05) 





Intracellular cytokine staining of CP CD8 + T cells. A-D: CD8+ T cells of HLA-B*57 positive CP 
were either freshly isolated (left) or stimulated with either wild type (center) or escape variant 
(right) HLA-B*57-restricted Gag peptides for 7 days. CPs were either on suppressive HAART 
regiments with undetectable viral loads (circles), were on HAART regimens but recently had 
detectable levels of viremia (triangles), or were not on HAART and had high levels of viremia 
(diamond). Cells from each group underwent an overnight stimulation with individual peptides. 
Percentage of CD8+ T cells expressing IFN-γ when restimulated with TW10 (A), KF11 (B), and 
IW9 (C) in blue, or the escape mutant variant peptide containing T242N/G248A (A), A163S (B), 
and I147L (C) mutations in red is shown. E-H: Percentage of CD8+ T cells expressing both IFN-γ 
and perforin after overnight stimulation with TW10 (E), KF11 (F), and IW9 (G) in blue, or the 
escape mutant variant peptide containing T242N/G248A (E), A163S (F), and I147L (G) mutations 
in red is shown. D and H show CD8+ T cells that express IFN-γ or co-express IFN-γ and perforin 
when PBMCs were stimulated overnight with Gag 263-272 (KK10, HLA-B*27+ peptide). Black 
asterisks indicate statistically significant difference (P < 0.05) between samples when restimulated 
with the same variant peptide; gray asterisks indicates statistically significant difference (P < 0.05) 





Theoretical nonlinear regression curves plotted with each escape variant. Data 
generated in fitness assay is shown here (wild type, black; I147L, orange; A146P, navy; 
A163S, red; A146P/A163S, purple; T242N/G248A, brown; A146P/A163S/T242N/G248A, 
teal). Black line depicts theoretical nonlinear regression curve generated by GraphPad. 
R2 values for each theoretical curve is show on the bottom right of individual plots. Plot 
on the bottom right depicts all theoretical curves corresponding to NL4-3 variant color on 





stimulation status for 
suppressive function. 
Suppressive capacity of 
CD8+ T cells, either 
unstimulated or 
stimulated with peptides 
corresponding to HLA-
B*57 Gag epitope (WT) or 
escape mutant variant 
(Mutant), is compared for 
each of seven different 
escape mutant variant 
viruses used (wild type, 
black; I147L, orange; 
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CHAPTER 2: ELITE SUPPRESSORS HAVE LOW LEVELS OF CELL-ASSOCIATED 
HIV-1 MRNA THAT INCREASE UPON T CELL ACTIVATION 
Christopher W Pohlmeyer*, C Korin Bullen*, Gregory M Laird*, Alyssa R Martin*, Stanley U Chioma, Victoria EK 
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Elite Controllers or Suppressors (ES) are patients who control HIV replication without 
antiretroviral therapy. In this study, we compared baseline and inducible HIV-1 mRNA 
levels in CD4+ T cells from ES and chronic progressors (CPs) receiving suppressive 
antiretroviral therapy.  
Design/Methods: 
We quantified basal levels of cell associated HIV-1 mRNA in CD4+ T cells isolated from 
CPs and ES. Additionally, we measured the fold upregulation of intracellular HIV-mRNA 
after stimulation of CD4+ T cells with phorbol 12-myristate 13-acetate (PMA) and 
ionomycin, and quantified the amount of HIV-mRNA levels released into culture 
supernatant.  
Results: 
ES have significantly less cell associated HIV-mRNA per 5x106 cells (p = 0.003); 8 of 10 
CPs had quantifiable HIV-1 mRNA at baseline, whereas this was present in only 2 of 10 
ES. Upon stimulation with PMA and ionomycin, 4 of 5 CPs and 7 of 9 ES showed 
increased cell associated HIV-mRNA. Interestingly, released HIV-1 mRNA could be 
detected in supernatants of CD4+ T cells stimulated with PMA/ionomycin from 5 of 8 ES.  
Conclusion: 
Our results demonstrate that while the baseline levels of cell associated HIV-1 mRNA 
are significantly lower in ES compared to CPs, stimulation of CD4+ T cells results in a 




Elite controllers or suppressors (ES) are individuals infected with HIV that maintain 
undetectable viral loads without receiving antiretroviral therapy (ART). Prior studies have 
shown that replication-competent virus can be cultured from CD4+ T cells from some 
ES7,8,9,10,23,25,85 and full genome sequence analysis of replication competent virus has not 
revealed the presence of mutations associated with attenuation1,23. Furthermore a recent 
study demonstrated that HIV-1 isolates from ES replicate vigorously and cause CD4+ T 
cell depletion in humanized mice23. Low levels of HIV-1 RNA can be detected in the 
plasma of most ES with ultrasensitive PCR assays18,86,87,88, and sequence analysis has 
revealed evolution of plasma virus present in these patients24,73,89,90,91. These studies 
suggest that there is ongoing low-level replication in these patients, and yet in spite of 
this, ES maintain very small latent reservoirs as measured by total10,15,92 and integrated 
DNA93 as well as by the quantitative viral outgrowth assay7 and the mouse viral 
outgrowth assay94. Despite the small reservoirs present in these patients, we 
hypothesized that ES would have relatively high levels of cell associated mRNA as a 
result of ongoing viral replication. 
 Hatano and colleagues have measured cell-associated in PBMCs isolated from ES88 
and have compared cell associated RNA present in CD4+ T cells of ES and CPs 
isolated from gut-associated lymphoid tissue95. These studies, however, did not 
specifically quantify HIV-1 mRNA which is a more direct indicator of HIV-1 
transcription96. In the present study, we measure baseline and inducible levels of cell 
associated HIV-mRNA in peripheral CD4+ T cells of ES and CPs using a previously 
validated primer probe set97. These results deepen our understanding of the HIV-1 latent 




Cell associated HIV-1 mRNA from unstimulated CD4+ T cells ex vivo was quantifiable in 
only 2 of 10 ES (median<10 copies/5M cells) as opposed to 8 of 10 CPs tested 
(median=92 copies/5M cells; p=0.03) (Figure 6a).  Proviral HIV DNA was measured in 
10 ES (median of 52 copies per 106 CD4+ T cells) and 10 CPs (median of 309 copies 
per 106 CD4+ T cells) to verify that our patients represent previously seen ES and CP 
cohorts (data not shown).  
To determine whether transcription was induced with T cell activation, we compared cell 
associated HIV-1 mRNA at baseline and after maximal T cell activation. Treatment of 
CD4+ T cells with the T cell activation control of PMA plus ionomycin (PMA/I) increased 
cell associated HIV-1 mRNA levels in 7 of 9 ES and 4 of 5 CPs (Figure 6b) . The 
measured cell associated HIV-1 mRNA per 106 CD4+ T cells remained statistically 
higher for CPs (median=33,676 per 106 cells) than for ES (median=873 per 106 cells) 
(p=0.047). However, there was no statistical difference between fold increase of cell 
associated HIV-mRNA between ES (13.1-fold, interquartile range=12.1) and CPs (19.2-
fold, interquartile range=13.4, p=0.22) per 106 stimulated cells.  Interestingly, cell 
associated HIV-1 mRNA levels remained below the limit of detection in 2 ES after 
stimulation with PMA and ionomycin stimulation.  
We also assessed the effect of T cell activation on viral release into culture supernatant. 
Upon stimulation of replicates of 5x106 CD4+ T cells from ES with PMA and ionomycin, 
HIV-1 mRNA was detected in the culture supernatant from 5 of 8 ES (Figure 6c). 3 ES 
(ES6, ES9, and ES42) had undetectable HIV-1 mRNA measurements in culture 
supernatant even when a total of 10-20x106 CD4+ T cells were stimulated.  In contrast, 
in ES22, ES23, and ES24 we detected HIV-1 mRNA in the culture supernatant from the 
majority of stimulated CD4+ T cell replicates.  Interestingly in ES36 and ES43, HIV-1 
mRNA was detected in the culture supernatant in only 1 of 5 stimulated replicates, with 
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3,012 and 5,116 copies of HIV-1 mRNA present in the positive wells. The frequency of 
detected released HIV-1 RNA suggests an 89% probability by Poisson distribution that 
the signal observed reflects a single cell releasing virus, and our HIV-1 mRNA 
measurements fit with our recent estimates of the burst size of an infected CD4+ T cell in 
vitro98.  Thus of the 25x106 cells stimulated, it appears that only 1 cell harbored an 
inducible virus in both of these patients. Interestingly, ES36 and ES43 also had 
undetectable cell associated HIV-1 mRNA in 5x106 CD4+ T cells after stimulation with 
PMA and ionomycin.  Taken together, these data suggest that there is significant 
heterogeneity in the inducible HIV-1 reservoir seen in ES which is consistent with results 
obtained from the viral outgrowth assay7,23. 
DISCUSSION/CONCLUSION 
Control of HIV-1 without ART by ES can be considered a model of a functional cure of 
infection. We have previously shown that these patients harbor much lower frequencies 
of latently infected CD4+ T cells7 than CPs on suppressive ART regimens99, and in this 
study we further analyze the inducible reservoir in ES. We demonstrate that cell 
associated HIV-1 mRNA levels observed in ES CD4+ T cells at baseline were 
significantly lower than those observed in CPs. These results further characterize the 
nature the latent reservoir in ES patients recent studies that found that ES had low levels 
of HIV-1 RNA in peripheral blood and in the GALT88,95. However, despite the low 
baseline levels of HIV-1 mRNA, there was no significant difference in the fold increase of 
cell associated HIV-1 mRNA levels upon PMA and ionomycin stimulation in CD4+ T cells 
isolated from ES and CPs, suggesting a similar induction of transcription in response to 
PMA and ionomycin treatment in both patient populations. While we cannot determine if 
this increase in HIV-1 mRNA is due to transcription of defective or intact proviral 
sequences100, the data are consistent with our ability to culture replication-competent 
virus from some ES. 
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There was significant heterogeneity in the amount of cell associated and released virus 
seen in CD4+ T cells from different ES.  Interestingly, ES23 and ES24 had detectable 
HIV-1 mRNA at baseline and both patients had a relatively high frequency of CD4+ T 
cells that released virus into culture supernatant following T cell stimulation.  In contrast, 
the frequency of CD4+ T cells that released virus into culture supernatant was much 
lower in other ES. However we were able to culture and characterize replication-
competent virus from 2 such patients, ES99 and ES3624 in prior studies. Further studies 
will be needed to determine whether virus that is releases into culture supernatant 
following CD4+ T cell activation is in fact replication-competent. 
Studies have shown that virus in the plasma of ES evolves over time suggesting that 
there is ongoing viral replication24,73,89,90,91. In spite of that we still found very low levels of 
HIV-1 mRNA in peripheral CD4+ T cells in some of these patients. It is possible that the 
robust CTL response in these patients101 is able to eliminate transcriptionally active 
CD4+ T cells in peripheral blood that may be producing viral proteins, while CD4+ T cells 
in anatomical compartments that exclude CTL are the true source of ongoing viral 
replication.  Results from a recent study that found that CD8+ T cells are excluded from 
B cell follicles in ES monkeys may be consistent with this hypothesis102.   
In summary, we characterize baseline cell associated HIV-1 mRNA and show a robust 
upregulation following T cell stimulation in some ES.  The results will have implications 
for patients who are subjected to curative procedures but still have residual low level 
HIV-1 reservoirs. 
MATERIALS AND METHODS 
Study Participants: 
All studies were approved by the Johns Hopkins Institutional Review Board. All patients 
provided written informed consent before participation in this study. CPs are patients 
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with undetectable viral loads on suppressive ART regimens for at least 1 year. ES have 
maintained undetectable viral loads by standard commercial assays without ART. 
Isolation of HIV-1 mRNA and DNA: 
PBMCs were isolated from fresh blood samples by Ficoll gradient centrifugation. CD4+ T 
Cells were isolated using Miltenyi CD4+ T Cell Isolation Kit and cultured in RPMI1640 
supplemented with 1% Pen/Strep and 10% FBS. 5x106 cells in 2 mL of complete media 
were either cultured in the presence of DMSO (0.2%) or PMA (50 ng/mL) and Ionomycin 
(2 µM) for 24 hours. This stimulation resulted in greater than 90% of T cell activation as 
determined by CD69 expression.  Supernatants were mixed with Trizol LS and cells 
were lysed using Trizol. Total RNA was isolated as described previously96. Human 
genomic DNA was isolated using Puregene kit (Qiagen) as per manufacturer’s 
instructions. 
Quantification of HIV-1 mRNA and DNA: 
Total intracellular RNA was reverse transcribed using qScript from Quanta Biosciences 
as per manufacturer’s instructions. Reverse transcribed HIV-1 mRNA was quantified as 
described previously96 using a primer and probe set that anneals to a highly conserved 
region of the 3’ end of HIV-1 mRNA97. The limit of quantification was set as the dilution 
point at which the Ct of the plasmid molecular standard replicates had an s.d. > 0.5. We 
determined that the limit of quantification for all intracellular HIV-mRNA transcripts was 
10 copies95.  HIV-1 proviral DNA levels were quantified by qPCR using ToughMix 
(Quanta Biosciences). Previously published primers that target a small region of Gag103 
were used to detect HIV-1 proviral DNA, and cellular input was quantified measuring 







HIV-mRNA before and after PMA and ionomycin stimulation. A HIV-mRNA isolated 
from CD4+ T cells of ES (blue triangles) and CPs (red triangles) was quantified by 
qPCR. Samples below the limit of detection are represented by open triangles. The 
black horizontal bar represents the median value of HIV-mRNA for each population. HIV-
mRNA levels observed were higher in CD4+ T cells of CPs than of ES (p = 0.003). B 
CD4+ T cells of ES (blue inverted triangles) and CPs (red inverted triangles) were 
stimulated with either DMSO or PMA and ionomycin for 24 hours and HIV-mRNA was 
isolated and quantified by qPCR. Fold upregulation upon PMA and ionomycin 
stimulation is plotted. An empty symbol indicates the limit of detection was used as the 
DMSO control value. No significance difference in fold upregulation was detected 
between the two populations (p = 0.27 with empty symbol, 0.24 without empty symbol). 
C HIV-mRNA release from CD4+ T cells upon PMA and ionomycin stimulation. 
Replicates of 5x106 CD4+ T cells from ES were stimulated with PMA and ionomycin for 
24 hours, and supernatant was collected for measurement of released HIV-mRNA. Open 
diamonds indicate replicates with supernatant values below the limit of detection. Single 
replicates from 2 ES (ES 36 and ES43) were positive, suggesting release of HIV-mRNA 
from individual cells.  
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SIGNIFICANCE AND FUTURE DIRECTIONS 
The data presented here represent individual studies performed in a single lab. If I have 
learned anything in graduate school, I have learned to not believe any single study (or 
series of studies if done by the same lab) until the results are confirmed independently. 
Nevertheless, the results discussed in this thesis suggest that some HIV-specific CD8+ 
T cells from ES are able to recognize both wild type and escape variant MHC-restricted 
epitopes. Without the ability to escape CTL control, viremia may be tempered. Activation 
and differentiation of naïve CD8+ T cells that express cross reactive T cell receptors may 
be critical targets for an effective therapeutic HIV vaccine. 
While CTL activity is more robust in the ES population, this doesn’t necessarily negate 
multiple factors being critical for the phenotype. Demonstrating that infected CD4+ T 
cells of ESs do not seem to have different levels of inducible intracellular HIV mRNA 
than CPs after maximal stimulation suggests that the resting state of latently infected 
CD4s is no different between the two populations. This supports the notion that more 
effective CTL control in CPs may lead to better control of viremia.  
Understanding the mechanism by which ES control viremia may not be sufficient for 
developing a therapeutic vaccine. Cross-sectional studies cannot delineate between 
cause or consequence of the ES phenotype, i.e. whether any observed phenotype is 
causing the host to control viremia or is merely a byproduct of the host’s control. It may 
be necessary to determine the cause of the ES phenotype in order to develop a 
therapeutic vaccine.  
In that regard, it is best to study patients during seroconversion. This is very difficult to 
do, because a) ES are a very small proportion of the HIV-infected population and b) they 
will not necessarily present to a clinic during acute infection as most ES do not suffer 
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from acute retroviral syndrome. To circumvent this issue, Indian rhesus macaques are 
often used as ES models, though pathogenesis of SIV is often quite different than HIV; 
additionally, the rhesus macaque ES model may not truly recapitulate what is observed 
in humans. 
Due to the enrichment of specific HLA molecules with the ES phenotype, studying 
seronegative donors that possess these protective alleles may shed some light on the 
cause of control. There is evidence to suggest that exposure to an antigen may induce 
an adaptive response against both the original antigen and HIV104. Screening healthy 
donors for HIV-specific CD8+ T cells could demonstrate that the cause of immunological 
control is a pre-existing HIV-specific memory response. As finding an individual who 
would become an ES is rather challenging, inducing an HIV-specific phenotype in a 
humanized mouse model followed by HIV challenge and monitoring HIV viral load levels 
and CD8+ T cell activity may provide useful information on ways to induce the ES 
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